Form 4: Ultragenyx CMO Eric Crombez Receives Equity Grant

Ultragenyx Pharmaceutical Inc. EVP and Chief Medical Officer Eric Crombez was granted 34,674 restricted stock units and 59,952 stock options.

Summary

• Eric Crombez, EVP and Chief Medical Officer of Ultragenyx Pharmaceutical Inc., received an equity award on April 16, 2026.
• The grant includes 34,674 Restricted Stock Units (RSUs) vesting over four years.
• The grant also includes 59,952 stock options with an exercise price of $24.52, expiring on April 16, 2036.
• Following these transactions, the reporting person holds 110,975 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of executive interests with long-term shareholder value through equity-based compensation.
• Retention of key leadership personnel in the Chief Medical Officer role.

Negatives

• Potential for future shareholder dilution upon the vesting and exercise of these equity awards.

Risks

• Vesting of equity is subject to continued employment and performance conditions.
• Market volatility may impact the future value of the granted options and RSUs.

Future Outlook

The equity grants are subject to standard vesting schedules: RSUs vest 1/4th annually over four years, and options vest 1/4th on the first anniversary followed by monthly vesting over the subsequent three years.

Management Comments

• The transactions were executed under the Company's 2023 Incentive Plan.

Industry Context

StockSavvy.ai notes that equity grants to C-suite executives in the biotechnology sector are standard practice for talent retention and aligning management incentives with long-term clinical and commercial milestones.

Comparison to Industry Standards

• The use of a four-year vesting schedule for RSUs and options is consistent with standard corporate governance practices for mid-cap biotechnology firms.
• The grant size is commensurate with the responsibilities of a Chief Medical Officer at a company of this market capitalization.

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual exercise of these options and vesting of RSUs.

Next Steps

• Vesting of the first tranche of RSUs on April 16, 2027.
• Vesting of the first tranche of stock options on April 16, 2027.

Key Dates

Keywords

Ultragenyx, RARE, Form 4, Insider Trading, Equity Compensation, Biotech